Roche's diagnostics division saw a year-over-year sales increase of 14% in 2020 to CHF 13.79bn ($15.3bn) – largely due to demand for COVID-19 diagnostics.
Roche Takes Advantage Of COVID-19 Testing Rush
Roche’s sales in 2020 increased by 1%, at constant exchange rates, to CHF 58.3bn, led by 14% growth in its diagnostics division.
More from In Vitro Diagnostics
More from Diagnostics
• By
Early diagnosis can be “detrimental” to patients, Suzanne O'Sullivan, neurologist and author of “The Age of Diagnosis,” argued at the Wired Health conference on 18 March. "You save one life from screening 2,000 women for breast cancer, but you also treat 10 women unnecessarily," she said.
• By
Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.
• By
The urine-based GAGome test showed promise in the first clinical results from the international AURORAX-0087A, in the largest study conducted on clear cell renal cell carcinoma, the most common type of kidney cancer.